Results 11 to 20 of about 7,331 (198)

Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration [PDF]

Mediators of Inflammation, 2010
Aims. Migration of CD4-positive lymphocytes into the vessel wall is a critical step in atherogenesis. Recent data suggest that ivabradine, a selective I(f)-channel blocker, reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice ...
Thomas Walcher, Peter Bernhardt, Dusica Vasic, Helga Bach, Renate Durst, Wolfgang Rottbauer, Daniel Walcher   +6 more
doaj   +2 more sources

Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure

Journal of Immunology Research, 2016
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions.
Ilonka Rohm, Daniel Kretzschmar, Rudin Pistulli, Marcus Franz, P. Christian Schulze, Christian Stumpf, Atilla Yilmaz   +6 more
doaj   +2 more sources

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation

ESC Heart Failure, 2022
Aims Ivabradine is indicated for heart failure (HF) patients with reduced ejection fraction (HFrEF), but limited data are available with regards to the use of ivabradine in those with a history of paroxysmal atrial fibrillation (AF). To assess the effect
Yu‐Sheng Lin, Jeng‐Yu Jan, Jung‐Jung Chang, Ming‐Shyan Lin, Teng‐Yao Yang, Po‐Chang Wang, Mien‐Cheng Chen   +6 more
doaj   +2 more sources

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study

Drug Design, Development and Therapy, 2013
Andreas O Doesch,1 Susanne Mueller,1 Christian Erbel,1 Christian A Gleissner,1 Lutz Frankenstein,1 Stefan Hardt,1 Arjang Ruhparwar,2 Philipp Ehlermann,1 Thomas Dengler,3 Hugo A Katus1 1Department of Cardiology, 2Department of Cardiovascular Surgery ...
Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA   +9 more
doaj   +1 more source

IVABRADINE OUTSIDE THE CLINICAL GUIDELINES: INTEREST OF A PRACTITIONER

Российский кардиологический журнал, 2018
The article is focused on the data concerning the influence of ivabradine on myocardial electrophysiology in experimental and clinical studies. It is shown that ivabradine decreases ventricular rate in chronic atrial fibrillation, and prevents the ...
E. I. Tarlovskaya
doaj   +3 more sources

Case report: Ivabradine induced Torsades de Pointes

IHJ Cardiovascular Case Reports, 2023
Ivabradine is used to control heart rate in patients of heart failure with reduced ejection fraction. Although considered safe, it is reported to prolong QTc interval when given with other QTc prolonging drugs or in setting of hypokalemia or ...
Mohit M. Bhagwati, K.K. Talwar, Amitabh Yaduvanshi   +2 more
doaj   +1 more source

Observational study of new-onset atrial fibrillation in patients treated with Ivabradine alone versus Ivabradine and β-blocker drug (The BetaBrad Study)

MGM Journal of Medical Sciences, 2022
Introduction: Ivabradine is a heart rate lowering agent by inhibiting Iƒ current in sinus node. It is approved for use in patients with angina and heart failure for heart rate control.
Rohan S Thanedar, Srinivas Kudva, Prakash Sanzgiri, Charan Reddy   +3 more
doaj   +1 more source

The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels

Frontiers in Pharmacology, 2022
Background and purpose: Ivabradine is clinically administered to lower the heart rate, proposedly by inhibiting hyperpolarization-activated cyclic nucleotide-gated cation channels in the sinoatrial node. Recent evidence suggests that voltage-gated sodium
Benjamin Hackl, Peter Lukacs, Janine Ebner, Krisztina Pesti, Krisztina Pesti, Nicholas Haechl, Mátyás C Földi, Mátyás C Földi, Elena Lilliu, Klaus Schicker, Helmut Kubista, Anna Stary-Weinzinger, Karlheinz Hilber, Arpad Mike, Arpad Mike, Hannes Todt, Xaver Koenig   +16 more
doaj   +1 more source

Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. [PDF]

PLoS ONE, 2012
BACKGROUND: Elevated heart rate is associated with increased cardiovascular morbidity. The selective I(f) current inhibitor ivabradine reduces heart rate without affecting cardiac contractility, and has been shown to be cardioprotective in the failing ...
Li Yue-Chun, Zhang Teng, Zhou Na-Dan, Ge Li-Sha, Luo Qin, Guan Xue-Qiang, Lin Jia-Feng   +6 more
doaj   +1 more source

Effects of selective heart rate reduction with ivabradine on LV function and central hemodynamics in patients with chronic coronary syndrome

International Journal of Cardiology: Heart & Vasculature, 2021
Objectives: We assessed left ventricular (LV) function and central hemodynamic effects in patients with a heart rate (HR) at rest of ≥70 beats per minute (bpm) and chronic coronary syndrome (CCS) after long-term treatment with ivabradine compared to ...
Anna Lena Hohneck, Peter Fries, Jonas Stroeder, Günther Schneider, Stephan Henrik Schirmer, Jan-Christian Reil, Michael Böhm, Ulrich Laufs, Florian Custodis   +8 more
doaj   +1 more source